It can scarcely be claimed the drug-eluting cardiovascular stent wars are over, but Abbott Vascular (Temecula, California) now has its bioresorbable vascular scaffold (BVS) in the fight, as the Everbio II trial makes clear. Lead investigator Stéphane Cook of the Hospital and University (Fribourg, Switzerland), said the trial suggested that the two device types were similar in terms of target lesion and all revascularization, but the two DES units bested the BVS on in-segment late lumen loss, which Cook said, "reinforces our primary hypothesis of DES superiority within the 6-12 month timeframe."